STEAP2

Summary

STEAP2 (STEAP2 metalloreductase, HGNC:17885) is a protein-coding gene on chromosome 7q21.13, encoding Metalloreductase STEAP2 (Q8NFT2). Integral membrane protein that functions as a NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce a Fe(3+) chelate that is bound on the other side of the membrane.

This gene is a member of the STEAP family and encodes a multi-pass membrane protein that localizes to the Golgi complex, the plasma membrane, and the vesicular tubular structures in the cytosol. A highly similar protein in mouse has both ferrireductase and cupric reductase activity, and stimulates the cellular uptake of both iron and copper in vitro. Increased transcriptional expression of the human gene is associated with prostate cancer progression. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Source: NCBI Gene 261729 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 79 total
• MANE Select transcript: NM_001244944

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17885
Approved symbol	STEAP2
Name	STEAP2 metalloreductase
Location	7q21.13
Locus type	gene with protein product
Status	Approved
Aliases	IPCA-1, STAMP1, STMP
Ensembl gene	ENSG00000157214
Ensembl biotype	protein_coding
OMIM	605094
Entrez	261729

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 20 protein_coding, 1 retained_intron

ENST00000287908, ENST00000394621, ENST00000394622, ENST00000394626, ENST00000394629, ENST00000394632, ENST00000402625, ENST00000426158, ENST00000428074, ENST00000482369, ENST00000880619, ENST00000880620, ENST00000880621, ENST00000880622, ENST00000930432, ENST00000930433, ENST00000930434, ENST00000966513, ENST00000966514, ENST00000966515, ENST00000966516

RefSeq mRNA: 6 — MANE Select: NM_001244944 NM_001040665, NM_001040666, NM_001244944, NM_001244945, NM_001244946, NM_152999

CCDS: CCDS43612, CCDS5615, CCDS59064

Canonical transcript exons

ENST00000394621 — 6 exons

Exon	Start	End
ENSE00001519014	90232337	90237683
ENSE00001519046	90216491	90216603
ENSE00003616543	90225050	90225574
ENSE00003850595	90211740	90212045
ENSE00003892100	90229872	90230036
ENSE00003893966	90226971	90227498

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 97.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.4655 / max 203.1695, expressed in 1122 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79439	4.5637	941
79437	4.4186	897
79438	0.2878	157
79436	0.1808	82
79435	0.0146	1

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pericardium	UBERON:0002407	97.45	gold quality
calcaneal tendon	UBERON:0003701	96.75	gold quality
prostate gland	UBERON:0002367	95.80	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.77	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.05	gold quality
middle temporal gyrus	UBERON:0002771	93.86	gold quality
epithelial cell of pancreas	CL:0000083	92.44	gold quality
kidney epithelium	UBERON:0004819	92.04	silver quality
cerebellar vermis	UBERON:0004720	90.37	gold quality
tendon	UBERON:0000043	89.91	gold quality
superior frontal gyrus	UBERON:0002661	89.75	gold quality
cartilage tissue	UBERON:0002418	89.14	gold quality
postcentral gyrus	UBERON:0002581	89.06	gold quality
parietal lobe	UBERON:0001872	88.89	gold quality
synovial joint	UBERON:0002217	88.08	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.33	gold quality
primary visual cortex	UBERON:0002436	87.13	gold quality
left ventricle myocardium	UBERON:0006566	86.85	gold quality
layer of synovial tissue	UBERON:0007616	86.79	gold quality
occipital lobe	UBERON:0002021	86.76	gold quality
oviduct epithelium	UBERON:0004804	86.48	gold quality
mucosa of transverse colon	UBERON:0004991	86.04	gold quality
pituitary gland	UBERON:0000007	85.86	gold quality
saphenous vein	UBERON:0007318	85.76	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.70	gold quality
vena cava	UBERON:0004087	85.66	silver quality
Brodmann (1909) area 9	UBERON:0013540	85.66	gold quality
ileal mucosa	UBERON:0000331	85.03	gold quality
entorhinal cortex	UBERON:0002728	85.02	gold quality
adenohypophysis	UBERON:0002196	84.93	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-75367	no	229.85
E-MTAB-7303	no	81.57
E-GEOD-36552	no	34.76
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

302 targeting STEAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754

Literature-anchored findings (GeneRIF, showing 16)

• cloning and characterization of STAMP1, which is expressed in both normal prostate and prostate neoplasms (PMID:12095985)
• STEAP2 is involved in the development of prostate cancer. As a cell-surface antigen, it is a potential diagnostic or therapeutic target in prostate cancer. (PMID:12429817)
• Expression of STAMP2, a gene highly similar to STAMP1 (STEAP2), in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation. (PMID:15897894)
• The murine ortholog, Steap2, is a ferrireductase, cupric reductase, and stimulates cellular uptake of both iron and copper in vitro. (PMID:16609065)
• STEAPs may represent novel markers of mesenchymal stem cells in man as well as mice. (PMID:19196137)
• Data suggest that STAMP1 is required for prostate cancer growth. (PMID:20587517)
• Over-expression of STEAP2 is associated with prostate cancer progression. (PMID:25248617)
• STEAP2 drives aggressive prostate cancer traits by promoting proliferation, migration and invasion and significantly influencing the transcriptional profile of ten genes underlying the metastatic cascade. (PMID:29674723)
• The conformational modulation of STEAP2 by the local membrane cholesterol content can therefore serve as a potential mechanism to modulate STEAP2 function in a compartment-restricted manner (PMID:29940176)
• STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo. (PMID:31696760)
• The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer. (PMID:32802887)
• Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. (PMID:34649092)
• METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. (PMID:35436987)
• STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2. (PMID:36316642)
• STEAP2 promotes hepatocellular carcinoma progression via increased copper levels and stress-activated MAP kinase activity. (PMID:38830975)
• Unveiling the role of copper metabolism and STEAP2 in idiopathic pulmonary fibrosis molecular landscape. (PMID:38872435)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	steap2	ENSDARG00000062887
mus_musculus	Steap2	ENSMUSG00000015653
rattus_norvegicus	Steap2	ENSRNOG00000006076

Paralogs (4): STEAP1B (ENSG00000105889), STEAP3 (ENSG00000115107), STEAP4 (ENSG00000127954), STEAP1 (ENSG00000164647)

Protein

Protein identifiers

Metalloreductase STEAP2 — Q8NFT2 (reviewed: Q8NFT2)

Alternative names: Prostate cancer-associated protein 1, Protein up-regulated in metastatic prostate cancer, Six-transmembrane epithelial antigen of prostate 2, SixTransMembrane protein of prostate 1

All UniProt accessions (5): Q8NFT2, B5MC02, C9JHX5, C9JLP2, Q6YPB2

UniProt curated annotations — full annotation on UniProt →

Function. Integral membrane protein that functions as a NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce a Fe(3+) chelate that is bound on the other side of the membrane. Mediates sequential transmembrane electron transfer from NADPH to FAD and onto heme, and finally to the Fe(3+) chelate. Can also reduce Cu(2+) to Cu(1+).

Subcellular location. Endosome membrane. Cell membrane.

Tissue specificity. Expressed at high levels in prostate and at significantly lower levels in heart, brain, kidney, pancreas, and ovary.

Similarity. Belongs to the STEAP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NFT2-1	1	yes
Q8NFT2-2	2
Q8NFT2-3	3

RefSeq proteins (6): NP_001035755, NP_001035756, NP_001231873, NP_001231874, NP_001231875, NP_694544 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013130	Fe3_Rdtase_TM_dom	Domain
IPR028939	P5C_Rdtase_cat_N	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR051267	STEAP_metalloreductase	Family

Pfam: PF01794, PF03807

Catalyzed reactions (Rhea), 2 shown:

• 2 Fe(2+) + NADP(+) + H(+) = 2 Fe(3+) + NADPH (RHEA:71767)
• 2 Cu(+) + NADP(+) + H(+) = 2 Cu(2+) + NADPH (RHEA:71771)

UniProt features (71 total): helix 20, binding site 15, strand 11, turn 7, transmembrane region 6, sequence variant 5, splice variant 2, sequence conflict 2, chain 1, modified residue 1, domain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9PGW	X-RAY DIFFRACTION	1.46
9PGX	X-RAY DIFFRACTION	1.46
9PGY	X-RAY DIFFRACTION	1.55
7TAI	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFT2-F1	89.09	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (15): 93–100; 118; 151; 152; 160; 229; 281; 302; 316 (axial binding residue); 319; 378; 395 …

Post-translational modifications (1): 483

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 223 (showing top): RORA1_01, GOBP_TRANSITION_METAL_ION_TRANSPORT, GOBP_INTRACELLULAR_IRON_ION_HOMEOSTASIS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, TGACCTY_ERR1_Q2, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_IRON_ION_TRANSPORT, GOBP_COPPER_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, COUP_01, GOBP_EXOCYTOSIS, GOBP_GOLGI_TO_PLASMA_MEMBRANE_TRANSPORT, BRN2_01, GOCC_COATED_VESICLE, GOBP_SECRETION

GO Biological Process (9): Golgi to plasma membrane transport (GO:0006893), endocytosis (GO:0006897), response to hormone (GO:0009725), copper ion import (GO:0015677), regulated exocytosis (GO:0045055), copper ion import across plasma membrane (GO:0098705), iron ion import across plasma membrane (GO:0098711), monoatomic ion transport (GO:0006811), iron ion transport (GO:0006826)

GO Molecular Function (4): cupric reductase (NADH) activity (GO:0008823), metal ion binding (GO:0046872), ferric-chelate reductase (NADPH) activity (GO:0052851), oxidoreductase activity (GO:0016491)

GO Cellular Component (8): Golgi membrane (GO:0000139), endosome (GO:0005768), early endosome (GO:0005769), cytosol (GO:0005829), plasma membrane (GO:0005886), endosome membrane (GO:0010008), trans-Golgi network transport vesicle (GO:0030140), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inorganic cation import across plasma membrane	2
bounding membrane of organelle	2
endosome	2
cellular anatomical structure	2
post-Golgi vesicle-mediated transport	1
vesicle-mediated transport to the plasma membrane	1
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
response to endogenous stimulus	1
response to chemical	1
copper ion transport	1
exocytosis	1
plasma membrane copper ion transport	1
iron import into cell	1
iron ion transmembrane transport	1
transport	1
transition metal ion transport	1
oxidoreductase activity, acting on metal ions, NAD or NADP as acceptor	1
cation binding	1
ferric-chelate reductase activity	1
catalytic activity	1
Golgi apparatus	1
endomembrane system	1
cytoplasmic vesicle	1
cytoplasm	1
membrane	1
cell periphery	1
cytoplasmic vesicle membrane	1
Golgi-associated vesicle	1
transport vesicle	1
clathrin-coated vesicle	1

Protein interactions and networks

STRING

568 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STEAP2	EEA1	Q15075	749
STEAP2	KLK2	P20151	739
STEAP2	ACP3	P15309	727
STEAP2	TGM4	P49221	720
STEAP2	SLC45A3	Q96JT2	697
STEAP2	KLKB1	P03952	683
STEAP2	CYBRD1	Q53TN4	670
STEAP2	PYCR1	P32322	649
STEAP2	KLK3	P07288	615
STEAP2	SLC11A2	P49281	603
STEAP2	MSMB	P08118	544
STEAP2	SLC39A14	Q15043	508
STEAP2	GBA1	P04062	497
STEAP2	SLC39A8	Q9C0K1	482
STEAP2	TEX47	Q8TBZ9	476
STEAP2	TFRC	P02786	476

IntAct

19 interactions, top by confidence:

A	B	Type	Score
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
DPEP1	ILVBL	psi-mi:“MI:0914”(association)	0.530
DPEP1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
ZPLD1	CEACAM8	psi-mi:“MI:0914”(association)	0.350
NS3	C15orf61	psi-mi:“MI:0914”(association)	0.350
	NBAS	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
CTXN1	ABCC4	psi-mi:“MI:0914”(association)	0.350
NDUFA4	XRCC2	psi-mi:“MI:0914”(association)	0.350
PARM1	ORC4	psi-mi:“MI:0914”(association)	0.350
VSTM1	FADS1	psi-mi:“MI:0914”(association)	0.350
SLC30A7	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A7	ESYT2	psi-mi:“MI:0914”(association)	0.350
NRAS	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350

BioGRID (23): STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-RNA), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Proximity Label-MS), STEAP2 (Proximity Label-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS), STEAP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GVZ9, A4IFN5, A5PK40, A6NH52, A6NI61, B2LYG4, B2RZC9, B6ID01, D2HKB0, D3ZG27, P86229, Q0VDI3, Q15012, Q15546, Q17QJ2, Q1RLT2, Q2TA01, Q4R4I5, Q4R6E8, Q5H8A4, Q5R7Q1, Q5RAH0, Q5RL79, Q5U3C3, Q5VTY9, Q5ZML7, Q64232, Q6PHN7, Q6QRN8, Q719N3, Q71SV0, Q8BWB6, Q8IY49, Q8N6M3, Q8NFT2, Q8R189, Q8VD53, Q8VDI9, Q8VDR5, Q9CQC4

Diamond homologs: Q4V8K1, Q5RKL5, Q658P3, Q687X5, Q6NZ63, Q8BWB6, Q8CI59, Q8NFT2, Q923B6, Q9CWR7, Q9GL50, Q9UHE8, O29370

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1218 predictions. Top by Δscore:

Variant	Effect	Δscore
7:90211940:GTCC:G	donor_gain	1.0000
7:90214649:G:GT	donor_gain	1.0000
7:90225572:CAGG:C	donor_loss	1.0000
7:90225573:AGGT:A	donor_loss	1.0000
7:90225574:GGTA:G	donor_loss	1.0000
7:90225575:GT:G	donor_loss	1.0000
7:90232328:T:A	acceptor_gain	1.0000
7:90211932:G:GT	donor_gain	0.9900
7:90222405:T:G	donor_gain	0.9900
7:90225044:CCCTA:C	acceptor_loss	0.9900
7:90225046:CTA:C	acceptor_loss	0.9900
7:90225047:TA:T	acceptor_loss	0.9900
7:90225048:A:AG	acceptor_gain	0.9900
7:90225048:A:T	acceptor_loss	0.9900
7:90225048:AG:A	acceptor_gain	0.9900
7:90225049:G:GC	acceptor_loss	0.9900
7:90225049:G:GG	acceptor_gain	0.9900
7:90225049:GG:G	acceptor_gain	0.9900
7:90225049:GGAT:G	acceptor_gain	0.9900
7:90225258:G:GT	donor_gain	0.9900
7:90225570:GGCAG:G	donor_gain	0.9900
7:90225571:GCAG:G	donor_gain	0.9900
7:90225571:GCAGG:G	donor_gain	0.9900
7:90225575:G:GG	donor_gain	0.9900
7:90225576:T:A	donor_loss	0.9900
7:90226965:CCACA:C	acceptor_loss	0.9900
7:90226966:CACA:C	acceptor_loss	0.9900
7:90226968:CA:C	acceptor_loss	0.9900
7:90226969:AGGTT:A	acceptor_loss	0.9900
7:90226970:G:GT	acceptor_loss	0.9900

AlphaMissense

3205 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:90225510:T:A	V143D	0.999
7:90225431:A:C	S117R	0.998
7:90225433:C:A	S117R	0.998
7:90225433:C:G	S117R	0.998
7:90225513:A:T	K144I	0.998
7:90225516:G:A	G145E	0.998
7:90229924:A:T	E358V	0.998
7:90229950:A:C	S367R	0.998
7:90229952:C:A	S367R	0.998
7:90229952:C:G	S367R	0.998
7:90225192:G:A	G37E	0.997
7:90225228:T:C	L49P	0.997
7:90225514:A:C	K144N	0.997
7:90225514:A:T	K144N	0.997
7:90225515:G:A	G145R	0.997
7:90225515:G:C	G145R	0.997
7:90227383:G:T	R302I	0.997
7:90227436:A:C	S320R	0.997
7:90227438:C:A	S320R	0.997
7:90227438:C:G	S320R	0.997
7:90229898:G:C	W349C	0.997
7:90229898:G:T	W349C	0.997
7:90229914:T:A	W355R	0.997
7:90229914:T:C	W355R	0.997
7:90229941:G:C	G364R	0.997
7:90229942:G:A	G364D	0.997
7:90230022:T:C	F391L	0.997
7:90230024:C:A	F391L	0.997
7:90230024:C:G	F391L	0.997
7:90225258:G:A	G59E	0.996

dbSNP variants (sampled 300 via entrez): RS1000005900 (7:90238012 C>A,T), RS1000014686 (7:90235069 A>T), RS1000048082 (7:90242589 C>T), RS1000076813 (7:90218601 A>G), RS1000181549 (7:90210678 T>C), RS1000219674 (7:90214686 C>A), RS1000238007 (7:90217739 G>A,C), RS1000253607 (7:90211037 C>G), RS1000368627 (7:90211395 G>A,C), RS1000382211 (7:90221224 C>T), RS1000692941 (7:90225021 T>C), RS1000735322 (7:90221494 T>A,C,G), RS1000903187 (7:90232559 T>C), RS1001050724 (7:90241108 A>G), RS1001135832 (7:90238477 T>C)

Disease associations

OMIM: gene MIM:605094 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006629_62	Pulse pressure	2.000000e-20
GCST007269_272	Pulse pressure	4.000000e-14

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression	6
sodium arsenite	decreases expression, affects splicing, increases expression	3
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
aristolochic acid I	decreases expression	1
trichostatin A	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
nickel sulfate	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	decreases methylation	1
Vorinostat	increases expression	1
Air Pollutants	decreases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Cisplatin	increases expression, affects cotreatment	1
Clorgyline	increases expression	1
Doxorubicin	decreases expression	1
Endosulfan	increases expression	1
Estradiol	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.